Full Text PDF Similar Articles Mail to Author

¹Department of Obstetrics and Gynecology, Kocaeli University, Faculty of Medicine, Kocaeli-Turkey
²Department of Medical Oncology, Kocaeli University, Faculty of Medicine, Kocaeli-Turkey
³Department of Pathology, Kocaeli University, Faculty of Medicine, Kocaeli-Turkey DOI : 10.5505/tjo.2020.2214 Ovarian metastasis is substantially rare in non-small cell lung cancer (N-SCLC). Driver gene mutations, such as Anaplastic Lymphoma Kinase (ALK), are used in the diagnosis of N-SCLC and its metastases. Demonstration of ALK mutation in N-SCLC patients will be helpful for detecting ovarian metastasis and planning personalized therapy; however, there is a limited number of cases related to this topic. In this case, we present the diagnosis and treatment of ALK-positive non-small cell lung adenocarcinoma patient with ovarian metastasis. Crizotinib is the first-class tyrosine kinase inhibitor using for the treatment of ALK-positive N-SCLC. The ovarian metastasis has been treated with surgery while under Crizotinib treatment. The patient continues to receive crizotinib treatment and no new metastases were detected at the end of a one-year follow-up. The possibility of ovarian metastasis in female N-SCLC patients with ALK rearrangement should be kept in mind. Keywords : Anaplastic Lymphoma Kinase (ALK); crizotinib; lung adenocarcinoma; metastasis; ovary